+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Kidney Fibrosis - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762896
  • Report
  • April 2019
  • Region: Global
  • 130 pages
  • VPA Research


  • AdAlta Ltd
  • CisThera Inc
  • Fibrocor Therapeutics LP
  • iBio Inc
  • MedPacto Inc
  • Pharmaxis Ltd

Kidney Fibrosis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Kidney Fibrosis R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Kidney Fibrosis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Kidney Fibrosis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Kidney Fibrosis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Kidney Fibrosis pipeline Profiled in detail

Key players actively participating in Kidney Fibrosis pipeline are profiled along with their R&D progress in Kidney Fibrosis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Kidney Fibrosis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Kidney Fibrosis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Kidney Fibrosis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Kidney Fibrosis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Kidney Fibrosis pipeline study
  • All recent news and developments related to Kidney Fibrosis drugs are provided
Note: Product cover images may vary from those shown


  • AdAlta Ltd
  • CisThera Inc
  • Fibrocor Therapeutics LP
  • iBio Inc
  • MedPacto Inc
  • Pharmaxis Ltd
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Kidney Fibrosis Disease Overview

3. Kidney Fibrosis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Kidney Fibrosis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Kidney Fibrosis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Kidney Fibrosis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Kidney Fibrosis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • AdAlta Ltd
  • Angion Biomedica Corp
  • BiOrion Technologies BV
  • Cellmid Ltd
  • Certa Therapeutics Pty Ltd
  • CisThera Inc
  • Ember Therapeutics Inc
  • Epigen Biosciences Inc
  • Evotec AG
  • Fibrocor Therapeutics LP
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Genzyme Corp
  • iBio Inc
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Medikine Inc
  • MedPacto Inc
  • Nash Pharmaceuticals Inc
  • NB Health Laboratory Co Ltd
  • Novo Nordisk AS
  • Osteoneurogen Inc
  • PharmAkea Therapeutics Inc
  • Pharmaxis Ltd
  • ProMetic Life Sciences Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • Scholar Rock Inc
  • Symic Biomedical Inc
  • Vascular Biogenics Ltd
  • Vectus Biosystems Ltd
Note: Product cover images may vary from those shown